Clinical Trials Logo

Filter by:
NCT ID: NCT00333411 Completed - Psoriasis Clinical Trials

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the treatment of moderate to severe plaque-type psoriasis. This new medicine will be compared to a so-called placebo medicine over 12 weeks with a 12 weeks treatment extension possible.

NCT ID: NCT00333138 Completed - Multiple Sclerosis Clinical Trials

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.

NCT ID: NCT00333073 Completed - Clinical trials for Urinary Incontinence

Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence

Start date: March 2006
Phase: N/A
Study type: Interventional

To assess effectiveness of Bulkamid® injection in females suffering from stress or mixed (stress and urge) urinary incontinence after 12 months follow up period

NCT ID: NCT00332943 Completed - Colorectal Cancer Clinical Trials

MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil

Start date: December 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Barium or BariumFerumoxsil is better for fecal tagging in MR colonography. Patients referred to colonoscopy are offered MR colonography before colonoscopy. Two days before colonography, patients ingest either a contrast agent A (200 ml Barium sulphate solution 1g/ml)) four times a day or a 200 ml contrast agent B (Barium sulfate(25%) and Ferumoxil(75%)) four times a day, which will render fecal masses "invisible" on the following MR colonography. The patients are randomised to either contrast agent A or B. The examinations are evaluated by two independent blinded readers, who will rate the tagging quality of the contrast agents. The quality of tagging will be rated by a Visual Analog Scale (VAS) and Relative contrast (ReCon = Iwall - Ilumen/ Iwall + Ilumen).

NCT ID: NCT00332865 Completed - Clinical trials for Head and Neck Cancer

Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy

Start date: June 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Dysphagia is a common side effect after radiotherapy for haed and neck cancer patients. It may be worsened by immobility of the throat during tube feeding. Hypothesis: Exercises may prevent or reduce late dysphagia. Method: Phase I study to identify the tolerated intensity of exercises and establish the method of measuring training intensity and dysphagia measurement. Endpoint: Objective dysphagia using VF and FEESST. The HN swallowing and HN pain endpoint of EORTC H&N35 questionnaire. Weight loss, duration of tube feeding.

NCT ID: NCT00332592 Completed - Clinical trials for Necrotizing Enterocolitis

Intragastric and Peritoneal Microdialysis in Infants With Necrotizing Enterocolitis (NEC)

Start date: October 2006
Phase: Phase 4
Study type: Observational

NEC is a serious inflammatory bowel disease, which almost only strikes infants with low birth weight and low gestational age. The morbidity and mortality rates are high, and early diagnosis and treatment is mandatory. The primary aim of the present study is to investigate the clinical use of intragastric microdialysis and whether it is able to select patients, who may benefit from either medical or surgical therapy. The aim of intraperitoneal microdialysis is to evaluate whether changes in intraperitoneal microdialysis reflect the clinical outcome after laparotomy.

NCT ID: NCT00332267 Completed - Healthy Clinical Trials

Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia

Start date: May 2006
Phase: N/A
Study type: Interventional

The objective of the present protocol is to study whether a low level of oxygen in the blood will affect the immune response to as well as cerebral blood flow and metabolism during an infection and, conversely, whether the acute systemic and cerebral physiologic response to hypoxia is modified by an ongoing inflammatory response.

NCT ID: NCT00332202 Completed - Clinical trials for Non Hodgkin Lymphoma

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.

NCT ID: NCT00332020 Completed - Clinical trials for Venous Thromboembolism

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

RECORD 2
Start date: February 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.

NCT ID: NCT00332007 Completed - Migraine With Aura Clinical Trials

Tonabersat in the Prophylaxis of Migraine With Aura

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Overall trial objectives: 1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura 2. How well tolerated is treatment with tonabersat The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment